Use of biologics for the management of Crohn's disease : IG-IBD clinical guidelines based on the GRADE methodology
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
A cure for Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract of unknown etiology, is not available, so patients require lifelong management to keep inflammation under control. The therapeutic armamentarium has expanded with approval of several biological drugs, including infliximab, adalimumab, vedolizumab and ustekinumab - monoclonal antibodies that target different inflammatory pathways - and darvadstrocel, a suspension of expanded human allogeneic, adipose-derived, mesenchymal stromal cells for the treatment of refractory complex perianal fistula. Notwithstanding existing practice guidelines on medical therapy for CD, the Italian Group for the Study of Inflammatory Bowel Disease felt the need to issue new guidelines focused on the use of biologics for managing the intestinal manifestations of CD and based on the GRADE methodology. This document presents recommendations regarding six clinical settings, from the induction to the maintenance of clinical remission, and from optimization and de-escalation of treatments to dealing with perianal CD and post-operative recurrence. The 19 evidence-based statements are supported by information on the quality of the evidence, agreement rate among panel members, and panel comments mainly based on evidence from real world studies.
| Errataetall: |
CommentIn: Dig Liver Dis. 2023 Jul;55(7):989. - PMID 37193630 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 55(2023), 4 vom: 15. Apr., Seite 442-453 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Macaluso, Fabio Salvatore [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 21.07.2023 published: Print-Electronic CommentIn: Dig Liver Dis. 2023 Jul;55(7):989. - PMID 37193630 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2023.01.155 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35298953X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35298953X | ||
| 003 | DE-627 | ||
| 005 | 20231226054956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2023.01.155 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM35298953X | ||
| 035 | |a (NLM)36792429 | ||
| 035 | |a (PII)S1590-8658(23)00166-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Macaluso, Fabio Salvatore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of biologics for the management of Crohn's disease |b IG-IBD clinical guidelines based on the GRADE methodology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Dig Liver Dis. 2023 Jul;55(7):989. - PMID 37193630 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a A cure for Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract of unknown etiology, is not available, so patients require lifelong management to keep inflammation under control. The therapeutic armamentarium has expanded with approval of several biological drugs, including infliximab, adalimumab, vedolizumab and ustekinumab - monoclonal antibodies that target different inflammatory pathways - and darvadstrocel, a suspension of expanded human allogeneic, adipose-derived, mesenchymal stromal cells for the treatment of refractory complex perianal fistula. Notwithstanding existing practice guidelines on medical therapy for CD, the Italian Group for the Study of Inflammatory Bowel Disease felt the need to issue new guidelines focused on the use of biologics for managing the intestinal manifestations of CD and based on the GRADE methodology. This document presents recommendations regarding six clinical settings, from the induction to the maintenance of clinical remission, and from optimization and de-escalation of treatments to dealing with perianal CD and post-operative recurrence. The 19 evidence-based statements are supported by information on the quality of the evidence, agreement rate among panel members, and panel comments mainly based on evidence from real world studies | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a Clinical guidelines | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a GRADE | |
| 650 | 4 | |a IG-IBD | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Papi, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Ambrogio |e verfasserin |4 aut | |
| 700 | 1 | |a Festa, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Bonovas, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Pansieri, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Piovani, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorino, Gionata |e verfasserin |4 aut | |
| 700 | 1 | |a Fantini, Massimo Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Caprioli, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Daperno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) |e verfasserin |4 aut | |
| 700 | 0 | |a Working panel |e verfasserin |4 aut | |
| 700 | 0 | |a Review panel |e verfasserin |4 aut | |
| 700 | 1 | |a Bertani, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Bezzio, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Bodini, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Bossa, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Buda, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Calabrese, Emma |e investigator |4 oth | |
| 700 | 1 | |a Furfaro, Federica |e investigator |4 oth | |
| 700 | 1 | |a Leone, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Mocciaro, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Onali, Sara |e investigator |4 oth | |
| 700 | 1 | |a Pastorelli, Luca |e investigator |4 oth | |
| 700 | 1 | |a Previtali, Enrica |e investigator |4 oth | |
| 700 | 1 | |a Principi, Mariabeatrice |e investigator |4 oth | |
| 700 | 1 | |a Renna, Sara |e investigator |4 oth | |
| 700 | 1 | |a Ribaldone, Davide Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Rispo, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Rizzello, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Saibeni, Simone |e investigator |4 oth | |
| 700 | 1 | |a Sampietro, Gianluca Matteo |e investigator |4 oth | |
| 700 | 1 | |a Savarino, Edoardo |e investigator |4 oth | |
| 700 | 1 | |a Testa, Anna |e investigator |4 oth | |
| 700 | 1 | |a Variola, Angela |e investigator |4 oth | |
| 700 | 1 | |a Viscido, Angelo |e investigator |4 oth | |
| 700 | 1 | |a Ardizzone, Sandro |e investigator |4 oth | |
| 700 | 1 | |a Biancone, Livia |e investigator |4 oth | |
| 700 | 1 | |a Cappello, Maria |e investigator |4 oth | |
| 700 | 1 | |a Castiglione, Fabiana |e investigator |4 oth | |
| 700 | 1 | |a Ciccocioppo, Rachele |e investigator |4 oth | |
| 700 | 1 | |a Comberlato, Michele |e investigator |4 oth | |
| 700 | 1 | |a Costa, Francesco |e investigator |4 oth | |
| 700 | 1 | |a D'Incà, Renata |e investigator |4 oth | |
| 700 | 1 | |a Danese, Silvio |e investigator |4 oth | |
| 700 | 1 | |a Di Sabatino, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Fries, Walter |e investigator |4 oth | |
| 700 | 1 | |a Gionchetti, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Latella, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Manguso, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Mastronardi, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Meucci, Gianmichele |e investigator |4 oth | |
| 700 | 1 | |a Milla, Monica |e investigator |4 oth | |
| 700 | 1 | |a Scribano, Maria Lia |e investigator |4 oth | |
| 700 | 1 | |a Vecchi, Maurizio |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 55(2023), 4 vom: 15. Apr., Seite 442-453 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:4 |g day:15 |g month:04 |g pages:442-453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2023.01.155 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 4 |b 15 |c 04 |h 442-453 | ||